| Literature DB >> 27163886 |
Pamela Berilyn T So1, Peter Rubio2, Stephen Lirio3, Allan Patrick Macabeo4, Hsi-Ya Huang3, Mary Jho-Anne T Corpuz5, Oliver B Villaflores6.
Abstract
The anti-angiotensin I converting enzyme activity of box jellyfish, Chiropsalmus quadrigatus Haeckel venom hydrolysate was studied. The venom extract was obtained by centrifugation and ultrasonication. Protein concentration of 12.99 μg/mL was determined using Bradford assay. The pepsin and papain hydrolysate was tested for its toxicity by Limit test following the OECD Guideline 425 using 5 female Sprague-Dawley rats. Results showed that the hydrolysate is nontoxic with an LD50 above 2000 mg/kg. In vitro angiotensin I converting enzyme (ACE) inhibitory activity was determined using ACE kit-WST. Isolation of ACE inhibitory peptides using column chromatography with SP-Sephadex G-25 yielded 8 pooled fractions with fraction 3 (86.5%) exhibiting the highest activity. This was followed by reverse phase - high performance liquid chromatography (RP-HPLC) with an octadecyl silica column (Inertsil ODS-3) using methanol:water 15:85 at a flow rate of 1.0 mL/min. Among the 13 fractions separated with the RP-HPLC, fraction 3.5 exhibited the highest ACE inhibitory activity (84.1%). The peptide sequence ACPGPNPGRP (IC50 2.03 μM) from fraction 3.5 was identified using Matrix-assisted laser desorption/ionization with time-of-flight tandem mass spectroscopy analysis (MALDI-TOF/MS).Entities:
Keywords: ACE; Box jellyfish; Chiropsalmus quadrigatus; Hypertension; Venom
Mesh:
Substances:
Year: 2016 PMID: 27163886 DOI: 10.1016/j.toxicon.2016.04.050
Source DB: PubMed Journal: Toxicon ISSN: 0041-0101 Impact factor: 3.033